生长激素以外的促生长疗法研究进展

Progress on growth promoting therapies other than growth hormone

重组人生长激素是身材矮小症儿童的经典治疗药物。近年来随着儿童生长机制的进一步探明,生长激素以外的促生长疗法的研究取得较大进展。重组人胰岛素样生长因子1是治疗原发性胰岛素样生长因子1缺乏的主要药物。C型钠尿肽为因软骨发育不全导致身材矮小症儿童提供了治疗选择。生长激素释放肽类似物能刺激生长激素释放,用于促生长治疗。此外,促性腺激素释放激素激动剂、芳香化酶抑制剂等可延缓患儿骨龄进展,对改善终身高有一定益处。现就这些除生长激素以外的促生长疗法研究进展进行综述,以期为临床身材矮小症患儿的治疗提供更多选择。

Recombinant human growth hormone is a classical therapeutic drug for children with short stature.In recent years,as the mechanism of growth in children has been further explored,growth-promoting therapies other than growth hormone have made great progress.Recombinant human insulin-like growth factor(IGF)-1 is the main treatment for primary IGF-1 deficiency,and C-type natriuretic peptide(CNP)offers a therapeutic option for children with short stature due to chondrodysplasia.Growth hormone-releasing peptide analogues stimulate growth hormone release and may be used for growth-promoting therapy.In addition,gonadotropin-releasing hormone analogue(Gn RHa)and aromatase inhibitors may delay the bone age in children and may be beneficial in improving final height.In this article,the research progress of growthpromoting therapies other than growth hormones is reviewed to provide more options for the clinical treatment of children with short stature.